# Fagron ## Facts | | | |---|---| | Founded | 1990 | | Origin | Netherlands | | Headquarters | Rotterdam | | Status | Active | | Previous names | Arseus NV (name of the listed group until renamed Fagron NV; the Fagron brand name itself dates from 1990) | | Manufacturing | EMEA, North America, Latin America | | Distribution | Salon & professional | | Website | https://fagron.com/ | Fagron is a pharmaceutical-compounding group that was founded in Rotterdam, the Netherlands, in 1990 by Ger van Jeveren [10]. Compounding is the preparation of a medicine made to order for one patient, for example when a standard dose or formulation does not exist, or when a patient reacts badly to the mass-produced version. Fagron supplies the raw materials, ready-made bases, equipment and services that pharmacists, prescribers and hospitals use for that work. It is first and foremost a business-to-business supplier rather than a consumer beauty brand, but several of its product lines reach into skin and hair care: the Neogen hair-care range, the TrichoConcept bases for hair-loss treatment, the Cleoderm cream base and the Nourisil MD silicone scar gel. For a name that dates only from 1990, Fagron has had a winding corporate path. It was bought by the Belgian group Omega Pharma in 2000, became part of the stock-listed Arseus group in 2007, and in the end gave its name to the whole listed company when Arseus NV was renamed Fagron NV at the close of 2014. Today the group is listed on Euronext Brussels and Euronext Amsterdam under the ticker FAGR, and it remains active, publishing results and holding shareholder meetings in 2026. ## Origin & founders Ger van Jeveren started Fagron in Rotterdam as a distributor of raw materials for medicines. That trade tied the young company to an old craft. Compounding, the creation and dispensing of tailor-made medications, is described as the historical foundation of the pharmacy profession. It lets pharmacists adapt a medicine to a patient's needs where the standard dose or formulation is not available, or where it causes an allergy. Supplying the pharmacists who still do this work was the business on which the company was built. Little else about its first decade is documented, beyond the fact that it remained a Dutch company until its takeover in 2000. ## History & milestones Around the turn of the century, the Belgian group Omega Pharma was following a "buy-and-build" strategy, acquiring smaller companies and grouping them into specialised divisions. Fagron was one of its more important purchases, taken over in 2000 [10]. In 2006, Omega Pharma brought its professional healthcare activities, which sold to health professionals rather than to consumers, together under a new umbrella organisation called Arseus. At its start, Arseus gathered some 35 small companies, and Fagron became part of the new structure. The following year, after a management buy-out, Arseus became an independent company through a stock-market listing on 5 October 2007, trading on Euronext Brussels and Euronext Amsterdam [10]. Omega Pharma kept 24% of the shares at first. The listed company's shares were later included in Belgium's BEL Mid index and the Amsterdam Small Cap Index (AScX). Arseus at that time was a broad healthcare supplier. Besides Fagron, it ran Arseus Dental, which sold dental equipment such as cameras and X-ray devices to dentists and dental laboratories; Arseus Medical, which supplied medical and surgical products to specialists, care homes, home-care nurses and hospitals; and Corilus, which made software for managing medical records and other healthcare information. In 2012, the group reorganised: Arseus Dental and Arseus Medical were replaced by two new divisions, Healthcare Solutions and Healthcare Specialities, while Fagron and Corilus carried on unchanged. The reorganisation did not last long. In 2014, the group sold the majority of Healthcare Solutions and Healthcare Specialities, which had been underperforming for some time. What remained was Fagron, Corilus and a new, small division called HL Technology, which developed and produced equipment for the dental and orthopaedic industries and accounted for only 3% of revenue in 2013. By December 2014, the company's own profile described Arseus as consisting of two divisions, Fagron and HL Technology, with Fagron supplying pharmaceutical raw materials, equipment, concepts and compounding to pharmacies and hospital pharmacies in 30 countries. With compounding now at the heart of the group, the name followed. An extraordinary general meeting of shareholders on 12 December 2014 approved changing the company name from Arseus NV to Fagron NV, and from 1 January 2015 the shares traded under the new ticker FAGR [9]. The brand that Omega Pharma had bought fourteen years earlier had become the name of the whole listed company. Figures from 2012 give a sense of Fagron's scale shortly before the rename: about 1,500 employees, turnover of US$400 million, a presence in 29 countries across Europe, Africa, the Americas, Asia and the Pacific, and some 150,000 customers in more than 55 countries. By 2025, the group reported revenue of €952 million, and it held a Capital Markets Day that year to present its strategic plan and financial objectives. ## Ownership Fagron has no parent company. Fagron NV is itself the publicly traded group, a company governed by Belgian law. Its ownership history runs through the Arseus years. After the 2007 listing, Omega Pharma still held a minority stake, which it sold to the private-equity investor Waterland in November 2009 [10]. Marc Coucke kept 11% of the shares through his investment company Couckinvest, and in 2014 he sold further shares, bringing his stake down to between 8% and 9%. The company's nationality depends on which part of the structure is meant. Fagron was founded in Rotterdam, and its head office remains there; the investor-relations office sits at Fascinatio Boulevard in Rotterdam [7]. The listed parent, however, is a Belgian company with its registered office in Waregem, Belgium [10]. The company's 2014 announcement described the same split: the Belgian listed company was based in Waregem, while the group's day-to-day operations were run by a Dutch subsidiary with its head office in Rotterdam. The brand's origin and working headquarters are Dutch; its legal domicile is Belgian. ## Philosophy & positioning Fagron sums up its purpose in one line: "Together we create the future of personalizing medicine." The company's own story is built around three ideas taken from that sentence. "Together" refers to working with pharmacists, prescribers, hospitals and industry so that they can offer quality, safety and service to their patients. "Create" describes the aim of offering the entire range of products and services needed to compound personalised medicine. "Personalizing medicine" is the goal itself, which the company links to better effectiveness, quality and safety as well as lower healthcare costs. The company gives several reasons why this work matters. It points to a growing and ageing world population. It argues that compounding extends the reach of mass-produced medication, so that treatment can be fitted to every patient. And it presents compounding as a way to keep medicines available: making drugs that are no longer sold commercially, and helping to resolve temporary drug shortages when governments request it. Fagron organises its business into a few broad areas. "Essentials" covers raw materials for compounding, repackaged under good manufacturing practice, along with packaging and supplies. "Brands" covers its own semi-finished products and bases, laboratory equipment, compounding software and pharmacogenomic testing, which looks at how a patient's genes may affect their response to a drug. "Compounding Services" covers sterile and non-sterile compounding and outsourcing for pharmacies and hospitals. An "Academy" provides training, courses and a video platform for pharmaceutical compounding. The company also runs a formulary, a database of customised formulas linked to the conditions for which they can be prescribed. According to the company, more than 400 pharmacists work within Fagron. Its customers are professionals, not the general public: the products are sold mainly to pharmacies, prescribers and hospitals, although the company also operates an online shop. ## Products & innovation Much of Fagron's own-brand range consists of "vehicles", the neutral bases into which a pharmacist mixes an active ingredient to make a finished medicine. SyrSpend is its range of oral suspending vehicles, used to turn a medicine into a liquid that can be swallowed. Pentravan is a transdermal base, designed to carry a drug through the skin. DiluCap is a line of excipients, the inactive ingredients that make up the bulk of a capsule formulation. FagronLab, a line of compounding equipment, is described by the company as the first global product line of its kind. The lines closest to beauty and personal care are built on the same idea. Cleoderm is a topical cream intended as a base for personalised dermatological treatments. Nourisil MD is a silicone scar gel; the company recommends it as a first-line therapy for both preventing and treating scars and keloids, and says it works by forming an invisible barrier over the scar and increasing hydration [4]. Pigmerise is a plant extract made from black pepper fruit, which Fagron offers for repigmentation treatment in conditions where the skin loses its colour, such as vitiligo. Fagron's hair-care work centres on TrichoTech, a plant-based active complex that the company describes as patented, although no patent number is published. According to Fagron, TrichoTech is associated with new hair growth by stimulating the "neogen phase", the stage of the hair cycle in which new hair is formed [4]. The technology appears in two lines. TrichoConcept is a range of compounding bases for personalised treatment of alopecia, meaning hair loss, which the company calls the first global line of multifunctional compounding vehicles with TrichoTech. Neogen is the cosmetics side of the same technology. Fagron describes it as the first line of cosmetics with TrichoTech, developed for personalised treatment of alopecia. The range consists of NeoOil, NeoWash and NeoCond, an oil, a shampoo and a conditioner. The company says NeoWash's complex is based on seven essential oils from Brazil's mountains. It also states that all Neogen products are cruelty-free and vegan, and free of parabens, propylene glycol, alcohol, dyes, petrolatum and 1,4-dioxane [6]. These are the company's own declarations and apply to the Neogen line only; no certifying body is named, and no third-party certifications are documented for the range. Fagron further reports an improvement in the structure of the hair cuticle, the hair's outer layer, after six applications of the combined products. ## Sustainability Fagron presents environmental, social and governance (ESG) work as part of its core strategy. Its framework has five areas: reducing its environmental impact, including greenhouse-gas emissions, energy use and waste; benefits for its employees; responsibility in the supply chain; giving back to communities, including access to healthcare; and good governance, covering compliance and the prevention of corruption. Chief executive Rafael Padilla has said that ESG is "central to our way of working". The company reports three headline figures for 2025: 73.3 million units of compounded medicine supplied, direct and energy-related greenhouse-gas emissions of 8,680 tonnes of CO2 equivalent, and an employee engagement score of 87% [8]. ## Current status Fagron is active. Its investor site lists full-year 2025 figures of €952 million in revenue, €193 million in recurring earnings before interest, taxes, depreciation and amortisation (REBITDA) and €92 million in net profit, along with results for the first half of 2026 and an ordinary and extraordinary general meeting held on 11 May 2026 [5]. The company says it is growing in Europe, the Middle East and Africa, North America and Latin America, with around 70 offices and compounding facilities. Its own pages give different figures for the size of its workforce, and neither is dated: the company's homepage cites 5,000 employees in more than 30 countries [2], while its ESG page refers to more than 3,000 colleagues [8]. Both are well above the roughly 1,500 employees recorded for 2012. ## Timeline {#belagg-timeline} | Year | Event | Source | |---|---|---| | 1990 | Founded in Rotterdam, the Netherlands, by Ger van Jeveren; distributed raw materials for medicines | https://en.wikipedia.org/wiki/Fagron | | 2000 | Taken over by the Belgian group Omega Pharma | https://en.wikipedia.org/wiki/Fagron | | 2000 | Fagron (Dutch company) taken over by Omega Pharma | https://en.wikipedia.org/wiki/Fagron | | 2007 | Arseus NV (Omega Pharma's former professional health division, including Fagron) listed via IPO on 5 October 2007 on Euronext Brussels and Euronext Amsterdam | https://en.wikipedia.org/wiki/Fagron | | 2009 | Omega Pharma sold its stake in Arseus to private-equity investor Waterland (November 2009) | https://en.wikipedia.org/wiki/Fagron | | 2009 | Omega Pharma sold its stake in Arseus (Fagron's then parent) to Waterland | https://en.wikipedia.org/wiki/Fagron | | 2014 | Arseus sold the majority of its Healthcare Solutions and Healthcare Specialities divisions, continuing with Fagron, Corilus and HL Technology | https://en.wikipedia.org/wiki/Fagron | | 2014 | EGM of Arseus NV (12 December 2014) approved renaming the company Fagron NV | https://investors.fagron.com/press-releases/arseus-extraordinary-general-meeting-of-shareholders-approves-all-motions/ | | 2014 | Arseus divested the majority of its Healthcare Solutions and Healthcare Specialities divisions | https://en.wikipedia.org/wiki/Fagron | | 2015 | Stock listing changed to Fagron, ticker FAGR, from 1 January 2015 | https://investors.fagron.com/press-releases/arseus-extraordinary-general-meeting-of-shareholders-approves-all-motions/ | | 2018 | US subsidiary Fagron, Inc. (St. Paul, Minnesota) introduced the TrichoConcept™ hair-care vehicle line in the United States (7 August 2018) — Tier 4 source | https://www.prnewswire.com/news-releases/fagron-inc-announces-new-hair-care-line---trichoconcept-300692834.html | | 2025 | Capital Markets Day 2025 (strategic plan and financial objectives) | https://fagron.com/ | | 2025 | Full-year 2025: revenue EUR 952m, REBITDA EUR 193m, net profit EUR 92m | https://investors.fagron.com/ | | 2026 | Ordinary and Extraordinary General Meeting held 11 May 2026; H1 2026 results published | https://investors.fagron.com/ | ## Signature products {#belagg-products} - **Neogen™ hair-care line (incl. NeoWash™ shampoo)** — Neogen™ is the first line of cosmetics with TrichoTech™ technology, a patented phytocomplex developed for personalized treatment of alopecia. — https://fagron.com/brands/neogen/ - **TrichoConcept™ (compounding vehicles for alopecia treatment)** — Fagron's TrichoConcept™ is the first global line of multifunctional compounding vehicles with TrichoTech™ technology, a Fagron patented phytocomplex specially developed for the use in personalized alopecia treatment. — https://fagron.com/brands/ - **Cleoderm™ (topical cream vehicle)** — Cleoderm™ is a topical cream designed to be used as a vehicle for the compounding of personalized dermatological treatments. — https://fagron.com/brands/ - **Nourisil™ MD (silicone scar gel)** — Nourisil™ MD silicone scar gel protects the scar by forming an invisible occlusive barrier — https://fagron.com/brands/ - **SyrSpend® (oral suspending vehicles)** — Fagron's range of oral suspending vehicles. — https://fagron.com/ ## Key ingredients {#belagg-ingredients} TrichoTech™ phytocomplex (7 essential oils) · Black pepper fruit phytocomplex (Piper nigrum L., in Pigmerise™) Source: https://fagron.com/brands/neogen/ ## Proprietary technologies & patents {#belagg-tech} - TrichoTech™ · Pigmerise™ · Pentravan® · DiluCap — https://fagron.com/brands/ - TrichoTech™ phytocomplex (described as patented; no patent number given) — https://fagron.com/brands/ ## Sources 2. (T1) https://fagron.com/ 4. (T2) https://fagron.com/brands/ 5. (T2) https://investors.fagron.com/ 6. (T2) https://fagron.com/brands/neogen/ 7. (T2) https://investors.fagron.com/contact/ 8. (T2) https://investors.fagron.com/esg-management-strategy/ 9. (T2) https://investors.fagron.com/press-releases/arseus-extraordinary-general-meeting-of-shareholders-approves-all-motions/ 10. (T3) https://en.wikipedia.org/wiki/Fagron --- Glowpedia · · Published 2026-09-30 Please cite with a link to the article URL.